Edgar Filing: IMARX THERAPEUTICS INC - Form 3/A

IMARX THERAPEUTICS INC

Form 3/A July 30, 2007

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

PEW THOMAS W JR

(Last)

(First)

C/O IMARX THERAPEUTICS,

(Middle)

Statement

(Month/Day/Year)

07/25/2007

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

IMARX THERAPEUTICS INC [IMRX]

4. Relationship of Reporting

Person(s) to Issuer

Filed(Month/Day/Year)

5. If Amendment, Date Original

07/25/2007

(Check all applicable)

10% Owner _X_ Director Officer Other (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

STREET

INC., 1635 EAST 18TH

TUCSON. AZÂ 85719

(Street)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security

(City)

(Instr. 4)

2. Amount of Securities

Beneficially Owned (Instr. 4)

33,913

3. Ownership

4. Nature of Indirect Beneficial

Ownership (Instr. 5)

Form: Direct (D) or Indirect (I)

(Instr. 5)

Â D

Common Stock

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security 2. Date Exercisable and (Instr. 4)

Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise

5. Ownership Form of Ownership

Derivative

6. Nature of Indirect Beneficial

(Instr. 5)

Price of Derivative Security:

Edgar Filing: IMARX THERAPEUTICS INC - Form 3/A

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	(1)	08/02/2014	Common Stock	11,000	\$ 15	D	Â
Stock Purchase Warrant (Right to Buy)	10/01/2003	09/29/2010	Common Stock	2,069	\$ 10	D	Â
Stock Purchase Warrant (Right to Buy)	01/30/2004	01/28/2011	Common Stock	505	\$ 10	D	Â
Stock Purchase Warrant (Right to Buy)	01/30/2004	01/28/2011	Common Stock	708	\$ 10	D	Â
Series A Preferred Stock	(2)	(3)	Common Stock	11,388 (4)	\$ (4)	D	Â
Series D Preferred Stock	(2)	(3)	Common Stock	10,025 (5)	\$ <u>(5)</u>	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	

PEW THOMAS W JR C/O IMARX THERAPEUTICS, INC. 1635 EAST 18TH STREET TUCSON, AZÂ 85719

 $\hat{A} X \qquad \hat{A} \qquad \hat{A} \qquad \hat{A}$

Signatures

Thomas W. Pew,
Jr.

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in four equal installments on each of August 2, 2005, 2006, 2007 and 2008, and may be exercised prior to vesting, subject to certain rights of repurchase by the Issuer.
- (2) These shares of Preferred Stock will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
- (3) Not applicable.
- (4) These shares of Preferred Stock will automatically convert into Common Stock upon the closing of the Issuer's initial public offering, and reflect a 2.75/2.63 conversion ratio, as adjusted to reflect a 6-for-10 and subsequent 1-for-3 reverse stock split.
- (5) These shares of Preferred Stock will automatically convert into Common Stock upon the closing of the Issuer's initial public offering, and reflect a 2.75/2.00 conversion ratio, as adjusted to reflect a 6-for-10 and subsequent 1-for-3 reverse stock split.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Reporting Owners 2

Edgar Filing: IMARX THERAPEUTICS INC - Form 3/A

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.